For other salt forms please inquire. Membrane-permeant inhibitor of the retinal type cGMP-gated ion channel (cGMP antagonist) but activator of cyclic GMP-dependent protein kinase I α and I ß (cGMP agonist). Suitable for distinction between kinase and ion channel mediated effects. Resistant against mammalian cyclic nucleotide-dependent phosphodiesterases, no metabolic side effects. More lipophilic and membrane-permeant compared to Sp-8-pCPT-cGMPS (Cat. No. C 014). Detailed technical information and updated reference list available on request. Reference: Butt et. al., Br. J. Pharmacol., 116, 3110 - 3116 (1995); Vignozzi et al., Prostate, 73, 1391 - 1402 (2013).
Cat. No. | P 008 |
CAS number | [172806-21-2] |
Purity | > 99% HPLC |
Salt form | Sodium |
Storage temperature | -20°C / -4°F |
Molecular formula | C₁₈H₁₄BrN₅O₆PS · Na |
Molecular weight [g/mol] | 562.3 |
Modifications | 1-cGMP, 2-cGMP, 8-cGMP |
Target | PKG (cGK) Activator |
Lipophilicity | 3.03 |
Absorption max [nm] | 256 |
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] | 40000 |